Shares of GlycoMimetics, Inc. (NASDAQ:GLYC) have been assigned a consensus rating of “Buy” from the six brokerages that are covering the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $13.50.
A number of research analysts have weighed in on GLYC shares. Zacks Investment Research raised shares of GlycoMimetics from a “hold” rating to a “buy” rating and set a $6.75 target price for the company in a research report on Thursday, October 27th. SunTrust Banks, Inc. reaffirmed a “buy” rating on shares of GlycoMimetics in a research report on Wednesday, November 30th. Finally, Canaccord Genuity set a $12.00 price objective on shares of GlycoMimetics and gave the company a “buy” rating in a research report on Tuesday, December 6th.
Shares of GlycoMimetics (NASDAQ:GLYC) opened at 6.10 on Wednesday. GlycoMimetics has a 12-month low of $3.70 and a 12-month high of $9.25. The stock’s 50 day moving average price is $6.25 and its 200-day moving average price is $6.94. The company’s market cap is $140.70 million.
GlycoMimetics (NASDAQ:GLYC) last released its earnings results on Friday, November 4th. The company reported ($0.34) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.10. On average, equities research analysts forecast that GlycoMimetics will post ($1.58) earnings per share for the current year.
In related news, Director Daniel M. Junius acquired 5,000 shares of the business’s stock in a transaction dated Tuesday, December 20th. The stock was acquired at an average price of $6.01 per share, with a total value of $30,050.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Helen M. Thackray sold 4,000 shares of the company’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $7.00, for a total transaction of $28,000.00. Following the transaction, the vice president now directly owns 156,715 shares of the company’s stock, valued at approximately $1,097,005. The disclosure for this sale can be found here. Insiders own 52.50% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Teachers Advisors LLC boosted its stake in GlycoMimetics by 32.6% in the third quarter. Teachers Advisors LLC now owns 14,375 shares of the company’s stock worth $103,000 after buying an additional 3,534 shares during the last quarter. Barclays PLC boosted its stake in GlycoMimetics by 77.1% in the second quarter. Barclays PLC now owns 15,816 shares of the company’s stock worth $115,000 after buying an additional 6,885 shares during the last quarter. Schwab Charles Investment Management Inc. acquired a new stake in GlycoMimetics during the second quarter worth $143,000. TFS Capital LLC acquired a new stake in GlycoMimetics during the second quarter worth $149,000. Finally, California State Teachers Retirement System acquired a new stake in GlycoMimetics during the second quarter worth $156,000. 79.82% of the stock is currently owned by institutional investors and hedge funds.
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.